posted on 2018-03-28, 00:00authored byDavid
P. Walsh, Robert D. Murphy, Angela Panarella, Rosanne M. Raftery, Brenton Cavanagh, Jeremy C. Simpson, Fergal J. O’Brien, Andreas Heise, Sally-Ann Cryan
The field of tissue
engineering is increasingly recognizing that
gene therapy can be employed for modulating in vivo cellular response thereby guiding tissue regeneration. However,
the field lacks a versatile and biocompatible gene delivery platform
capable of efficiently delivering transgenes to mesenchymal stem cells
(MSCs), a cell type often refractory to transfection. Herein, we describe
the extensive and systematic exploration of three architectural variations
of star-shaped poly(l-lysine) polypeptide (star-PLL) with
varying number and length of poly(l-lysine) arms as potential
nonviral gene delivery vectors for MSCs. We demonstrate that star-PLL
vectors are capable of self-assembling with pDNA to form stable, cationic
nanomedicines. Utilizing high content screening, live cell imaging,
and mechanistic uptake studies we confirm the intracellular delivery
of pDNA by star-PLLs to MSCs is a rapid process, which likely proceeds
via a clathrin-independent mechanism. We identify a star-PLL composition
with 64 poly(l-lysine) arms and five l-lysine subunits
per arm as a particularly efficient vector that is capable of delivering
both reporter genes and the therapeutic transgenes bone morphogenetic
protein-2 and vascular endothelial growth factor to MSCs. This composition
facilitated a 1000-fold increase in transgene expression in MSCs compared
to its linear analogue, linear poly(l-lysine). Furthermore,
it demonstrated comparable transgene expression to the widely used
vector polyethylenimine using a lower pDNA dose with significantly
less cytotoxicity. Overall, this study illustrates the ability of
the star-PLL vectors to facilitate efficient, nontoxic nucleic acid
delivery to MSCs thereby functioning as an innovative nanomedicine
platform for tissue engineering applications.